Yin Guo-Qiang, Li Zu-Lei, Li Dong
Department of Thoracic Surgery, Zibo Central Hospital, Zibo, Shandong Province, 255000, People's Republic of China.
Cancer Manag Res. 2022 Jun 29;14:2133-2141. doi: 10.2147/CMAR.S358620. eCollection 2022.
Neoadjuvant anti-programmed death receptor-1 (PD-1) blockade has been explored in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC). We conducted this study to assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC.
We retrospectively enrolled ESCC patients who received surgery within 3 months of treatment with camrelizumab plus chemotherapy from June 2019 to January 2021.
A total of 34 eligible patients were enrolled. The neoadjuvant treatment was well tolerated with no serious treatment-related adverse events. Thirty-two (94.1%) patients achieved a R0 resection, and 14 patients (41.2%) developed postoperative complications. The objective response rate (ORR) was 61.8% and the disease control rate (DCR) was 100.0%. The major pathological response (MPR), pathological complete response (pCR), and clinical to pathological downstaging rate were 50.0%, 35.3%, and 79.4%, respectively. With a median follow-up of 14.8 months, 30 (88.2%) patients who underwent surgical resection remain alive. The disease-free survival (DFS) and overall survival (OS) at 12 months were 86.4% and 92.8%, respectively.
Neoadjuvant camrelizumab plus chemotherapy is safe and efficacious in treating patients with locally advanced ESCC.
新辅助抗程序性死亡受体1（PD-1）阻断疗法已在局部晚期食管鳞状细胞癌（ESCC）的治疗中进行了探索。我们开展本研究以评估新辅助卡瑞利珠单抗联合化疗治疗局部晚期ESCC的疗效和安全性。
我们回顾性纳入了2019年6月至2021年1月期间接受卡瑞利珠单抗联合化疗治疗且在3个月内接受手术的ESCC患者。
共纳入34例符合条件的患者。新辅助治疗耐受性良好，未发生严重的治疗相关不良事件。32例（94.1%）患者实现R0切除，14例（41.2%）患者发生术后并发症。客观缓解率（ORR）为61.8%，疾病控制率（DCR）为100.0%。主要病理缓解（MPR）、病理完全缓解（pCR）和临床至病理降期率分别为50.0%、35.3%和79.4%。中位随访14.8个月，30例（88.2%）接受手术切除的患者仍存活。12个月时的无病生存率（DFS）和总生存率（OS）分别为86.4%和92.8%。
新辅助卡瑞利珠单抗联合化疗治疗局部晚期ESCC患者安全有效。
